Metacrine, Inc. (MTCR) Stock Analysis
DELISTED 2023
What happened to Metacrine, Inc. (MTCR) stock?
Metacrine, Inc. (MTCR) no longer trades on public markets. It was delisted in June 2023. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
- Delisting date:
- June 2023
- Last recorded price (historical):
- $0.5814 (last quote on record before the June 2023 delisting; historical, not a current quote)
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Metacrine, Inc. (MTCR). Metacrine, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for gastrointestinal diseases. Their lead product candidate, MET642, is in development for the treatment of ulcerative colitis.
Last analyzed: May 9, 2026Metacrine, Inc. (MTCR) Healthcare & Pipeline Overview
More about this archive record
Can I still buy MTCR shares?
No. MTCR stopped trading on public markets in June 2023, so the shares are not available through a broker. Anything you see quoted for MTCR elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before MTCR stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Metacrine, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.